<DOC>
	<DOCNO>NCT00058552</DOCNO>
	<brief_summary>The purpose study determine study drug pertuzumab effective treat patient advanced ovarian cancer refractory , recur following , prior chemotherapy .</brief_summary>
	<brief_title>A Study Evaluate Effect HER2 Activation rhuMAb 2C4 ( Pertuzumab ) Subjects With Advanced Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<criteria>Signed informed consent Willingness undergo tumor biopsy disease amenable biopsy ( Cohort 1 ) Age &gt; =18 year old Advanced , histologically document carcinoma ovary Measurable disease least one lesion accurately measure per RECIST least one dimension ( long dimension record ) . Each lesion must &gt; =20 mm measure conventional technique , include palpation , plain Xray , CT , MRI , &gt; =10 mm measure spiral CT. Or , clinically radiologically detectable disease ( e.g. , ascites , peritoneal deposit , mesenteric thicken lesion fulfill RECIST measurable disease ) . In addition , subject must two consecutive pretreatment CA 125 level great 2× institutional upper limit normal ( ULN ) &gt; =40 IU/mL , take least 1 week 3 month apart . The second two measurement CA 125 level drawn within 28 day follow screen biopsy . The late value must within 2 week start rhuMAb 2C4 treatment . One prior platinumbased chemotherapeutic regimen management primary disease contain carboplatin , cisplatin , another organoplatinum compound Life expectancy &gt; =12 week ECOG performance status 0 1 Use effective mean contraception ( woman childbearing potential ) Granulocyte count &gt; =1500/uL , platelet count &gt; =75,000/uL , hemoglobin &gt; =9 g/dL ( hemoglobin may support transfusion erythropoietin approve hematopoietic growth factor ; darbopoeitin [ Aranesp ] permit ) Serum bilirubin &lt; =1.5× ULN alkaline phosphatase , AST , ALT &lt; =2.5× ULN ( ALT , AST , alkaline phosphatase &lt; =5× ULN subject liver metastasis ) Serum creatinine &lt; =1.5× ULN International normalize ratio ( INR ) &lt; 1.5 activate partial thromboplastin time ( aPTT ) &lt; 1.5 ULN ( except subject receive warfarin ) Prior treatment experimental anticancer agent within 4 week prior Day 1 ( day first rhuMAb 2C4 infusion administer ) Prior treatment HER pathway inhibitor ( e.g. , Herceptin [ Trastuzumab ] , Iressa [ gefitinib ] , Tarceva [ erlotinib hydrochloride ] , C225 , CI1033 , TAK165 ) History clinical evidence central nervous system brain metastasis Ejection fraction , determine ECHO , &lt; 50 % Uncontrolled hypercalcemia ( &gt; 11.5 mg/dL ) Prior exposure doxorubicin liposomal doxorubicin &gt; 360 mg/m2 , mitoxantrone &gt; 120 mg/m2 , idarubicin &gt; 90 mg/m2 History malignancy within 5 year Day 1 except adequately treat carcinoma situ cervix , ductal carcinoma situ breast , basal squamous cell skin cancer History serious systemic disease , include active infection , uncontrolled hypertension ( diastolic blood pressure &gt; 100 mmHg two consecutive occasion ) , unstable angina , congestive heart failure , myocardial infarction within 6 month prior Day 1 , unstable symptomatic arrhythmia require medication ( subject chronic atrial arrhythmia , i.e. , atrial fibrillation , paroxysmal supraventricular tachycardia , control hypertension eligible ) Ongoing liver disease , include viral hepatitis , current alcohol abuse , cirrhosis Known human immunodeficiency virus infection Pregnancy lactation Major surgery significant traumatic injury within 3 week prior Day 1 exception tumor biopsy purpose study Inability comply study followup procedure Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render subject high risk treatment complication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Advanced , refractory , recurrent ovarian cancer</keyword>
</DOC>